AstraZeneca PLC operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares AstraZeneca PLC with three other
pharmaceutical manufacturers in Europe:
Novo Nordisk As
of DENMARK
(2020
sales of 126.95 billion Danish Kroner [US$19.79 billion]
of which 85%
was Diabetes and obesity),
Sanofi S.A.
of FRANCE
(37.37 billion Euros [US$43.35 billion]
of which 69%
was Pharmaceuticals), and
Merck KGaA
which is
based in GERMANY
(17.53 billion Euros [US$20.34 billion]
of which 43%
was Life Science).
Sales Analysis.
During the second
quarter of 2021, sales at AstraZeneca PLC totalled
£5.89 billion.
This is
an increase of 21.4%
from the £4.86 billion in sales at the company during the second quarter of 2020.
During the first two
quarters of 2021, sales totalled £11.20 billion, which is
14.6% higher
than through the first two quarters of 2020.
During the year ended December of 2020, sales at
AstraZeneca PLC were £20.59 billion (US$28.33 billion).
This
is
an
increase of 8.0%
versus 2019, when the company's sales were £19.06 billion.